Antistreptokinase antibodies: Implications for thrombolysis in a region with endemic streptococcal infection

Journal of Clinical Pathology

Volumn 58, Issue 9, 2005, Pages 1005-1007

  Blackwell, N ^a   Hollins, A ^a   Gilmore, G ^b   Norton, R ^b  

^a Mount Isa Base Hospital   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISTREPTOLYSIN; ENZYME ANTIBODY; STREPTOKINASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD CLOT LYSIS; ENDEMIC DISEASE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; POPULATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; CORONARY DISEASE; ENDEMIC DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUEENSLAND; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 24644514969     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.025312     Document Type: Article

References (12)

1. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander people. In: Australia's Health 2004. Canberra, Australia: Australian Institute of Health and Welfare, 2004:211-17.
2. Urdahl KB, Matthews JD, Currie BJ. Anti-streptokinase antibodies and streptokinase resistance in an Aboriginal population in Northern Australia. Aust NZ J Med 1996;26:49-53.
3. Carapetis JR, Wolf DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 1996;164:146-9.
4. Morris PS. Randomised controlled trials addressing Australian Aboriginal health needs: a systematic review of the literature. J Paediatr Child Health 1999;35:130-5.
5. Lynch M, Pentecost BL, Littler WA, et al. The significance of antistreptokinase antibodies. Clin Exp Immunol 1994;96:427-31.
6. Juhlin P, Bostrom P-A, Torp A, et al. Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction. J Int Med 1999;245:483-8.
7. Gemill JD, Hogg KD, Dunn FG, et al. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994;72:222-5.
8. Buchalter MB, Suntharalingham G, Jennings I, et al. Streptokinase resistance: when might streptokinase administration be ineffective? Br Heart J 1992;68:449-53.
9. Lynch M, Pentecost BL, Littler WA, et al. The distribution of antibodies to streptokinase. Postgrad Med J 1996;72:290-2.
10. Alexander T, Krishnaswami S, Khanduri U. Anti-streptokinase levels in Indian patients, Int J Cordial 1991;32:361-4.
11. Shaila G, Chandrashekar YS, Kumar N, et al. Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic with streptococcal infection and influence on reperfusion rates. Am J Cardiol 1994;74:187-9.
12. Anderson HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolysis in the treatment of myocardial infarction. N Engl J Med 2003;349:733-42.